Systemic manifestation and co-morbidity in COPD are associated with circulating markers of aging - COPD as a syndrome of accelerated aging

niversiteit Maastricht0 个研究点目标入组 800 人开始时间: 待定最近更新: 2024年5月6日

试验速览

暂无简介。

•For the COPD patients: diagnosis of COPD according to the American Thoracic Society (ATS) GOLD guidelines (FEV1 < 80% predicted and FEV1/FVC < 70% [18]; both male and female, age-range from 45 to 75 y; no respiratory tract infection or exacerbation of the disease for < 4 weeks before the study; capable of providing informed consent.
•For the healthy subjects: subjects without the objectively diagnosed diseases assessed in the present study: COPD, untreated diabetes mellitus type II, severe and untreated osteoporosis, severe renal failure or heart failure. Both male and female, age-range from 45 to 75 y will be included in the study.

•For the COPD patients and controls: any kind of carcinogenic pathology <5 y before study participation; chronic use of oral corticosteroids > 10mg/day; participation in any other studies involving investigational or marketed products concomitantly or < 4 weeks prior to entry into the study, investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements.

发起方